Physician profile
Karolina Faysman
NPI 1336320407
$1,086,642.25
in general payments reported to CMS, 2019-2025
37 companies · $258K in 2025
The $258K reported for 2025 was more than what 99% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $182K · 2022: $233K · 2023: $217K · 2024: $196K · 2025: $258K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $437K · Travel and Lodging: $131K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $59K · Food and Beverage: $23K · Consulting Fee: $21K · Honoraria: $1,320.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $436,913.25 |
| Travel and Lodging | $130,751.25 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $58,830.00 |
| Food and Beverage | $23,019.12 |
| Consulting Fee | $20,656.25 |
| Honoraria | $1,320.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $302,698.65 | 2021-2025 | Monjuvi, Jakafi, Niktimvo |
| Janssen Biotech, INC. | $171,406.62 | 2021-2025 | Carvykti, Rybrevant, Imbruvica |
| Sobi, INC | $133,289.62 | 2024-2025 | |
| Glaxosmithkline, LLC. | $93,634.57 | 2021-2025 | Ojjaara, Blenrep |
| Cti Biopharma Corp. | $87,038.79 | 2022-2023 | Vonjo |
| Pharmacyclics LLC, An Abbvie Company | $67,385.80 | 2021-2023 | Imbruvica |
| Jazz Pharmaceuticals INC. | $47,322.50 | 2021-2024 | |
| Pfizer INC. | $25,704.48 | 2021-2025 | |
| Syndax Pharmaceuticals, INC. | $25,086.83 | 2025 | Revuforj |
| E.R. Squibb & Sons, L.L.C. | $20,937.81 | 2021-2025 | Reblozyl |
| Abbvie INC. | $20,417.63 | 2022-2025 | |
| Genmab U.S., INC. | $16,086.57 | 2024-2025 | Epkinly |
| Beigene USA, INC. | $12,520.66 | 2022-2025 | Brukinsa |
| Sanofi-Aventis U.S. LLC | $11,892.32 | 2022-2024 | |
| Amgen INC. | $10,432.80 | 2021-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $10,375.87 | 2021-2023 | Xpovio |
| Takeda Pharmaceuticals U.S.A., INC. | $9,513.88 | 2021-2025 | Hyqvia |
| Secura Bio, INC. | $5,918.33 | 2021-2025 | Copiktra |
| Beone Medicines USA, INC. | $4,526.38 | 2025 | Brukinsa |
| Servier Pharmaceuticals LLC | $2,222.95 | 2023-2024 | |
| Kite Pharma, INC. | $1,600.00 | 2022 | |
| Astellas Pharma US INC | $1,325.00 | 2021-2022 | |
| Epizyme, INC. | $1,050.00 | 2021 | |
| Kadmon Pharmaceuticals LLC | $960.00 | 2021 | |
| Celgene Corporation | $911.58 | 2022-2025 | Reblozyl, Pomalyst |
| Blueprint Medicines Corporation | $900.00 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $263.14 | 2021-2025 | Calquence |
| Omeros Corporation | $250.00 | 2021 | |
| Genentech, INC. | $230.00 | 2023 | Columvi, Lunsumio |
| Tg Therapeutics, INC. | $185.00 | 2021 | |
| Genzyme Corporation | $178.00 | 2021 | |
| Daiichi Sankyo INC. | $132.43 | 2024-2025 | Vanflyta |
| Rigel Pharmaceuticals, INC. | $99.71 | 2023-2024 | Rezlidhia, Tavalisse |
| Springworks Therapeutics, INC. | $53.71 | 2024-2025 | Gomekli |
| Janssen Scientific Affairs, LLC | $40.90 | 2022 | |
| Geron Corporation | $25.40 | 2025 | Rytelo |
| Legend Biotech USA INC. | $24.32 | 2025 | Carvykti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karolina Faysman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.